He wake forest institute for regenerative medicine (WFIRM) has over two decades of experience using a variety of 3D printing modalities to develop implantable human tissue constructs
Active Cooperative Agreement Awarded
- Award ID
- D25AC00320
- Recipient
-
Wake Forest University Health Sciences UEI SN7KD2UK7GC5
- Awarding agency
-
Interior Business Center
Office of Policy Management and Budget, Department of the Interior
- Obligated
- $13,431,738
Award facts
- Assistance listing
- 93.384 ADVANCED RESEARCH PROJECTS AGENCY for HEALTH (ARPA-H)
- Completion date 38% complete
- Place of performance
- North Carolina, USA
Award details come from USAspending.gov.
Description
Over time the cellular compositions and implant dimensions relevant to clinical applications have increased requiring an integrated vascular system that allows perfusion of the entire construct. These bioprinted vascularized tissue constructs open the possibility of supporting a functional microanatomy that can perform nuanced organ specific functions. The overall strategy will include a protocol for cost effective clinical manufacturing of a sufficient number of autologous renal cells from a small surgical sample or tissue biopsy. These cells will be combined with a functionalized hydrogel bioink that both supports the long term viability of the embedded cells and promotes the activation of endogenous developmental pathways that guide the formation of a functional cellular microanatomy. Cutting edge multiphysics modeling will be applied to native renal tissue to establish a blueprint that approximates renal tissue architecture at a resolution of 50 UM. Software will also be developed to translate this blueprint into a printable code that will guide the rapid production of rudimentary renal tissue. These constructs will be further enhanced through maturation in a specialized perfusion bioreactor with an integrated sensor suite that monitors tissue function. Strategies will also be developed using small and large preclinical animal models to promote further remodeling of bioprinted renal tissue following implantation. The overarching goal is the production of bioprinted vascularized autologous renal tissue to augment renal function in patients suffering from kidney disease. This tissue therapy will be qualified using IND enabling preclinical animals in parallel with a commercialization plan to make this a cost efficient solution to the nations growing donor organ shortage.
Quick answers
Who received award D25AC00320?
D25AC00320 was awarded to Wake Forest University Health Sciences by Interior Business Center (Office of Policy Management and Budget) on September 26, 2025.
How much is award D25AC00320 worth?
$13,431,738 has been obligated on D25AC00320.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award